Stockscreener 앱 받기
15.61
1.14%
-0.18
시간 외 거래:
15.50
-0.11
-0.70%
전일 마감가:
$15.79
열려 있는:
$15.82
하루 거래량:
1.01M
Relative Volume:
0.46
시가총액:
$1.11B
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-6.787
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
+5.69%
1개월 성능:
-13.71%
6개월 성능:
-71.54%
1년 성능:
-64.74%
1일 변동 폭
$15.27
$15.82
1주일 범위
$14.82
$16.15
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
15.61 | 1.12B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
(MLTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Assessing Growth Potential with an 18% Upside - DirectorsTalk Interviews
A Look At MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Analyst Calls And FDA Fast Track Decision - simplywall.st
BioTech Breakout: MoonLake Up 30% On FDA Wins - Finviz
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy rating on Moonlake stock with $32 target - Investing.com Nigeria
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Growth in Short Interest - MarketBeat
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play - Finviz
MoonLake stock surges after FDA grants Fast Track designation for PPP treatment - Investing.com Nigeria
MoonLake Says FDA Grants its Sonelokimab Fast Track Designation for Palmoplantar Pustulosis Treatment - marketscreener.com
MoonLake announces FDA granted Fast Track designation for sonelokimab - TipRanks
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab in Treating Moderate-to-Severe Palmoplantar Pustulosis - Quiver Quantitative
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - The Manila Times
FDA Fast Tracks MoonLake drug for severe palmoplantar pustulosis - Stock Titan
Aug Fed Impact: What is the cash position of MoonLake Immunotherapeutics2025 Historical Comparison & Fast Entry High Yield Tips - baoquankhu1.vn
Weekly Earnings: What are the risks of holding Tesla IncQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Aug Opening: What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 News Drivers & Growth Focused Entry Point Reports - baoquankhu1.vn
Portfolio Update: Does MoonLake Immunotherapeutics have declining or rising EPSBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
How MoonLake Immunotherapeutics stock performs in weak economyWeekly Gains Report & Short-Term Trading Opportunity Alerts - mfd.ru
Can MoonLake Immunotherapeutics keep up with sector leadersMarket Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a Biotech Innovator’s Growth Potential with an 11% Upside - DirectorsTalk Interviews
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
1.24%
0.19%
자본화:
|
볼륨(24시간):